The IBBL partners with Luxembourg scientists and with globally recognized research centres to support world-class medical research and stimulate advances in personalised medicine to address the critical health issues affecting populations in Luxembourg and those around the world.

The IBBL is an integral partner in the Personalized Medicine Consortium (PMC) in Luxembourg, the umbrella organization, which links the key organizations involved in translational medical research, including the three leaders of the Luxembourg Health Sciences and Technologies Action Plan: the Luxembourg Centre for Systems Biomedicine (LCSB), the IBBL and the Lung Cancer Programme (and the Programme in Personalized Medicine - PPM, within CRP-Santé).

The role of the PMC is to create programmes in research and evaluation that make Luxembourg a world-leader in the adoption of new advances in personalized medicine into the healthcare system in Luxembourg. The PMC coordinates the activities, builds synergy and avoids duplication of efforts and resources.

The PMC will initially focus on three disease areas where Luxembourg is able to create excellent research programs that will advance science and have the potential to impact morbidity and mortality associated with the diseases: cancer (lung, colon and breast), Type 2 diabetes and Parkinson’s disease. In addition, the PMC will create a normal population cohort to serve as controls for studies and to provide important data on the demographics of disease in Luxembourg.

The IBBL supports the PMC by facilitating the creation of research teams in the four priority research areas, by collecting the appropriate tissues and data, and in providing some background characterization of tissue samples as needed by the research teams. Each disease team is composed of a complex array of individuals and organizations to ensure that it has the expertise needed to conduct the research.